UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. __)*

BioLineRx Ltd.
(Name of Issuer)
Ordinary Shares, par value NIS 0.01 per share
(Title of Class of Securities)
09071M106
(CUSIP Number)
December 11, 2014
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the
Notes).

CUSIP No.	<u>09071M106</u>				
1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Rima Senvest Management, L.L.C.				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	()			
3.	SEC USE ONLY	(a) [_] (b) [X]			
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH					
5.	SOLE VOTING POWER				
	0				
6.	SHARED VOTING POWER				
	26,286,450				
7.	SOLE DISPOSITIVE POWER				
	0				
8.	SHARED DISPOSITIVE POWER				
	26,286,450				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	26,286,450*				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	6.7%*				
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	OO, IA				
* Represented by 2,278,995 American Depositary Shares ("ADRs"). Each ADR represents 10 Ordinary Shares, par value NIS 0.01 per share. Further represented by 349,650 warrants, which may be exchanged for 349,650 ADRs.					

CUSIP No.	. <u>09071M106</u>				
1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Richard Mashaal				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	() .			
2		(a) [_] (b) [X]			
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Canada				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH					
5.	SOLE VOTING POWER				
	0				
6.	SHARED VOTING POWER				
	26,286,450				
7.	SOLE DISPOSITIVE POWER				
	0				
8.	SHARED DISPOSITIVE POWER				
	26,286,450				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	26,286,450*				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11.	6.7%*				
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
12.					
	IN, HC				
	ted by 2,278,995 American Depositary Shares ("ADRs"). Each ADR represents 10 Ordinary Shares, par value NIS 0.01 per shall by 349,650 warrants, which may be exchanged for 349,650 ADRs.	re. Further			

Item 1.	(a).	Name of Issuer:
		BioLineRx Ltd.
	(b).	Address of issuer's principal executive offices:
		P.O. Box 45158 19 Hartum Street Jerusalem 9777518, Israel
Item 2.	(a).	Name of person filing:
		Rima Senvest Management, L.L.C. Richard Mashaal
	(b).	Address or principal business office or, if none, residence:
		Rima Senvest Management, L.L.C. 540 Madison Avenue, 32 nd Floor New York, New York 10022
		Richard Mashaal c/o Rima Senvest Management, L.L.C. 540 Madison Avenue, 32 nd Floor New York, New York 10022
	(c).	Citizenship:
		Rima Senvest Management, L.L.C. – Delaware Richard Mashaal – Canada
	(d).	Title of class of securities:
		Ordinary Shares, par value NIS 0.01 per share
	(e).	CUSIP No.:
		09071M106

CUSIP No. <u>09071M106</u>

Item 3.		If Thi	This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a				
	(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).				
	(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).				
	(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).				
	(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.	S.C. 80a-8).			
	(e)		An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);				
	(f)		An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);				
	(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);				
	(h)		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);				
	(i)	[_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);					
	(j)		A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);				
	(k)		Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance (J), please specify the type of institution:	ance with §240.13d-1(b)(1)(ii)			
Item 4.	Ownership.						
	Provid	de the foll	lowing information regarding the aggregate number and percentage of the class of securities of the	issuer identified in Item 1.			
	(a)	Amo	unt beneficially owned:				
		Rima Senvest Management, L.L.C. – 26,286,450 Richard Mashaal – 26,286,450					
	(b)	Perce	ent of class:				
			a Senvest Management, L.L.C. – 6.7% ard Mashaal – 6.7%				
	(c)	Numl	ber of shares as to which the person has:				
		Rima	Senvest Management, L.L.C.				
		(i)	Sole power to vote or to direct the vote	0			
		(ii)	Shared power to vote or to direct the vote	26,286,450			
		(iii)	Sole power to dispose or to direct the disposition of	0			
		(iv)	Shared power to dispose or to direct the disposition of	26,286,450			
		Richa	ard Mashaal:				
		(i)	Sole power to vote or to direct the vote	0			
		(ii)	Shared power to vote or to direct the vote	26,286,450			
		(iii)	Sole power to dispose or to direct the disposition of	0			
		(iv)	Shared power to dispose or to direct the disposition of	26,286,450			
	Instru	Instruction: For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).					

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

All securities reported in this Schedule 13G are directly owned by advisory clients of Rima Senvest Management, L.L.C. None of the advisory clients individually owns more than 5% of BioLineRx's Ordinary Shares, par value NIS 0.01 per share.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 7, 2015 (Date)

RIMA SENVEST MANAGEMENT, L.L.C.

By: /s/ George Malikotsis
George Malikotsis
Vice President

RICHARD MASHAAL

By: /s/ Richard Mashaal*

(Signature)

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

^{*}The Reporting Person disclaims beneficial ownership in the shares reported herein except to the extent of his pecuniary interest therein.

AGREEMENT

The undersigned agree that this Schedule 13G dated January 7, 2015 relating to the Ordinary Shares, par value NIS 0.01 per share, of BioLineRx Ltd. shall be filed on behalf of the undersigned.

January 7, 2015

(Date)

RIMA SENVEST MANAGEMENT, L.L.C.

By: /s/ George Malikotsis

George Malikotsis Vice President

RICHARD MASHAAL

By: /s/ Richard Mashaal

(Signature)

SK 01780 0004 6323092